BACKGROUND: Children with Down syndrome have an increased risk of developing acute lymphoblastic leukemia and a poor tolerance of methotrexate. This latter problem is assumed to be caused by a higher cellular sensitivity of tissues in children with Down syndrome. However, whether differences in pharmacokinetics play a role is unknown. DESIGN AND METHODS: We compared methotrexate-induced toxicity and pharmacokinetics in a retrospective case-control study between patients with acute lymphoblastic leukemia who did or did not have Down syndrome. Population pharmacokinetic models were fitted to data from all individuals simultaneously, using non-linear mixed effect modeling. RESULTS: Overall, 468 courses of methotrexate (1-5 g/m(2)) were given to 44 acute lymphoblastic leukemia patients with Down syndrome and to 87 acute lymphoblastic leukemia patients without Down syndrome. Grade 3-4 gastrointestinal toxicity was significantly more frequent in the children with Down syndrome than in those without (25.5% versus 3.9%; P=0.001). The occurrence of grade 3-4 gastrointestinal toxicity was not related to plasma methotrexate area under the curve. Methotrexate clearance was 5% lower in the acute lymphoblastic leukemia patients with Down syndrome (P=0.001); however, this small difference is probably clinically not relevant, because no significant differences in methotrexate plasma levels were detected at 24 and 48 hours. CONCLUSIONS: We did not find evidence of differences in the pharmacokinetics of methotrexate between patients with and without Down syndrome which could explain the higher frequency of gastrointestinal toxicity and the greater need for methotrexate dose reductions in patients with Down syndrome. Hence, these problems are most likely explained by differential pharmaco-dynamic effects in the tissues between children with and without Down syndrome. Although the number of patients was limited to draw conclusions, we feel that it may be safe in children with Down syndrome to start with intermediate dosages of methotrexate (1-3 g/m(2)) and monitor the patients carefully.
BACKGROUND:Children with Down syndrome have an increased risk of developing acute lymphoblastic leukemia and a poor tolerance of methotrexate. This latter problem is assumed to be caused by a higher cellular sensitivity of tissues in children with Down syndrome. However, whether differences in pharmacokinetics play a role is unknown. DESIGN AND METHODS: We compared methotrexate-induced toxicity and pharmacokinetics in a retrospective case-control study between patients with acute lymphoblastic leukemia who did or did not have Down syndrome. Population pharmacokinetic models were fitted to data from all individuals simultaneously, using non-linear mixed effect modeling. RESULTS: Overall, 468 courses of methotrexate (1-5 g/m(2)) were given to 44 acute lymphoblastic leukemiapatients with Down syndrome and to 87 acute lymphoblastic leukemiapatients without Down syndrome. Grade 3-4 gastrointestinal toxicity was significantly more frequent in the children with Down syndrome than in those without (25.5% versus 3.9%; P=0.001). The occurrence of grade 3-4 gastrointestinal toxicity was not related to plasma methotrexate area under the curve. Methotrexate clearance was 5% lower in the acute lymphoblastic leukemiapatients with Down syndrome (P=0.001); however, this small difference is probably clinically not relevant, because no significant differences in methotrexate plasma levels were detected at 24 and 48 hours. CONCLUSIONS: We did not find evidence of differences in the pharmacokinetics of methotrexate between patients with and without Down syndrome which could explain the higher frequency of gastrointestinal toxicity and the greater need for methotrexate dose reductions in patients with Down syndrome. Hence, these problems are most likely explained by differential pharmaco-dynamic effects in the tissues between children with and without Down syndrome. Although the number of patients was limited to draw conclusions, we feel that it may be safe in children with Down syndrome to start with intermediate dosages of methotrexate (1-3 g/m(2)) and monitor the patients carefully.
Authors: Christian M Zwaan; Gertjan J L Kaspers; Rob Pieters; Karel Hählen; Gritta E Janka-Schaub; Christina H van Zantwijk; Dieuwke R Huismans; Esther de Vries; Marianne G Rots; Godefridus J Peters; Gerrit Jansen; Ursula Creutzig; Anjo J P Veerman Journal: Blood Date: 2002-01-01 Impact factor: 22.113
Authors: S Yamada; T Hongo; S Okada; C Watanabe; Y Fujii; H Hori; M Yazaki; R Hanada; Y Horikoshi Journal: Int J Hematol Date: 2001-12 Impact factor: 2.490
Authors: J M Chessells; G Harrison; S M Richards; C C Bailey; F G Hill; B E Gibson; I M Hann Journal: Arch Dis Child Date: 2001-10 Impact factor: 3.791
Authors: W A Kamps; J P M Bökkerink; F G A J Hakvoort-Cammel; A J P Veerman; R S Weening; E R van Wering; J F van Weerden; J Hermans; R Slater; E van den Berg; W G Kroes; A van der Does-van den Berg Journal: Leukemia Date: 2002-06 Impact factor: 11.528
Authors: M L Garré; M V Relling; D Kalwinsky; R Dodge; W R Crom; M Abromowitch; C H Pui; W E Evans Journal: J Pediatr Date: 1987-10 Impact factor: 4.406
Authors: Anjo J Veerman; Willem A Kamps; Henk van den Berg; Eva van den Berg; Jos P M Bökkerink; Marrie C A Bruin; Marry M van den Heuvel-Eibrink; Carin M Korbijn; Elisabeth T Korthof; Karin van der Pal; Theo Stijnen; Margreet H van Weel Sipman; J Fransje van Weerden; Elisabeth R van Wering; Anna van der Does-van den Berg Journal: Lancet Oncol Date: 2009-09-09 Impact factor: 41.316
Authors: Torben S Mikkelsen; Caroline F Thorn; Jun J Yang; Cornelia M Ulrich; Deborah French; Gianluigi Zaza; Henry M Dunnenberger; Sharon Marsh; Howard L McLeod; Kathy Giacomini; Mara L Becker; Roger Gaedigk; James Steven Leeder; Leo Kager; Mary V Relling; William Evans; Teri E Klein; Russ B Altman Journal: Pharmacogenet Genomics Date: 2011-10 Impact factor: 2.089
Authors: Johan G C van Hasselt; Natasha K A van Eijkelenburg; Jos H Beijnen; Jan H M Schellens; Alwin D R Huitema Journal: Br J Clin Pharmacol Date: 2013-07 Impact factor: 4.335
Authors: M A H den Hoed; E Lopez-Lopez; M L te Winkel; W Tissing; J D E de Rooij; A Gutierrez-Camino; A Garcia-Orad; E den Boer; R Pieters; S M F Pluijm; R de Jonge; M M van den Heuvel-Eibrink Journal: Pharmacogenomics J Date: 2014-11-04 Impact factor: 3.550
Authors: Ryan J Beechinor; Patrick A Thompson; Michael F Hwang; Ryan C Vargo; Lisa R Bomgaars; Jacqueline G Gerhart; ZoAnn E Dreyer; Daniel Gonzalez Journal: Clin Pharmacokinet Date: 2019-07 Impact factor: 6.447
Authors: Laura B Ramsey; John C Panetta; Colton Smith; Wenjian Yang; Yiping Fan; Naomi J Winick; Paul L Martin; Cheng Cheng; Meenakshi Devidas; Ching-Hon Pui; William E Evans; Stephen P Hunger; Mignon Loh; Mary V Relling Journal: Blood Date: 2012-12-11 Impact factor: 22.113